Temozolomide

Temozolomide Reactions 1680, p319 - 2 Dec 2017 Thrombocytopenia and nausea: case report An 8-year-old boy developed thrombocytopenia and nausea during treatment with temozolomide [route and times to reactions onsets stated; not all outcomes stated]. The boy was diagnosed with an anaplastic oligodendroglioma in the frontal lobe with local leptomeningeal involvement and periventricular subcallosal extension, for which he underwent a near total resection and also had a 1p/19q codeletion. He was started on temozolomide 200 mg/m /day for five days every 28 days for a total of 12 cycles. He tolerated the temozolomide therapy well except for the development of thrombocytopenia and minor nausea. The boy’s temozolomide therapy was delayed once for thrombocytopenia, and his nausea was relieved using ondansetron. His tumour was an isocitrate dehydrogenase wild-type tumour, which showed MGMT gene promoter methylation and harboured a BRAF alteration, an ATRX mutation and CHEK1 frameshift mutation. Author comment: "Based on the favorable cytogenetics (but prior to the IDH sequencing, which was only available later), conservative management with [temozolomide] 200 mg/m daily for 5 days every 28 days for 12 cycles was employed. Therapy was well tolerated with one delay for thrombocytopenia and minor nausea relieved with ondansetron." Sorge C, et al. Complete durable response of a pediatric anaplastic oligodendroglioma to temozolomide alone: Case report and review of literature. Pediatric Blood and Cancer 64: e26708, No. 12, Dec 2017. Available from: URL: http://doi.org/10.1002/pbc.26708 - USA 803284351 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Temozolomide

Reactions Weekly , Volume 1680 (1) – Dec 2, 2017
Free
1 page
Loading next page...
1 Page
 
/lp/springer_journal/temozolomide-Wi0RKG400I
Publisher
Springer International Publishing
Copyright
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
D.O.I.
10.1007/s40278-017-39250-2
Publisher site
See Article on Publisher Site

Abstract

Reactions 1680, p319 - 2 Dec 2017 Thrombocytopenia and nausea: case report An 8-year-old boy developed thrombocytopenia and nausea during treatment with temozolomide [route and times to reactions onsets stated; not all outcomes stated]. The boy was diagnosed with an anaplastic oligodendroglioma in the frontal lobe with local leptomeningeal involvement and periventricular subcallosal extension, for which he underwent a near total resection and also had a 1p/19q codeletion. He was started on temozolomide 200 mg/m /day for five days every 28 days for a total of 12 cycles. He tolerated the temozolomide therapy well except for the development of thrombocytopenia and minor nausea. The boy’s temozolomide therapy was delayed once for thrombocytopenia, and his nausea was relieved using ondansetron. His tumour was an isocitrate dehydrogenase wild-type tumour, which showed MGMT gene promoter methylation and harboured a BRAF alteration, an ATRX mutation and CHEK1 frameshift mutation. Author comment: "Based on the favorable cytogenetics (but prior to the IDH sequencing, which was only available later), conservative management with [temozolomide] 200 mg/m daily for 5 days every 28 days for 12 cycles was employed. Therapy was well tolerated with one delay for thrombocytopenia and minor nausea relieved with ondansetron." Sorge C, et al. Complete durable response of a pediatric anaplastic oligodendroglioma to temozolomide alone: Case report and review of literature. Pediatric Blood and Cancer 64: e26708, No. 12, Dec 2017. Available from: URL: http://doi.org/10.1002/pbc.26708 - USA 803284351 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680

Journal

Reactions WeeklySpringer Journals

Published: Dec 2, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve Freelancer

DeepDyve Pro

Price
FREE
$49/month

$360/year
Save searches from
Google Scholar,
PubMed
Create lists to
organize your research
Export lists, citations
Read DeepDyve articles
Abstract access only
Unlimited access to over
18 million full-text articles
Print
20 pages/month
PDF Discount
20% off